COVID-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-SARS-CoV-2 Activity at Low Concentrations; Clinical Trial Forthcoming
August 24, 2020 08:00 ET | Innovation Pharmaceuticals Inc.
Preliminary data shows Brilacidin’s Selectivity Index (SI), a ratio that compares a drug’s cytotoxicity and antiviral activity, to be greater than 300 in a human lung epithelial cell lineBrilacidin’s...
Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line
May 26, 2020 08:00 ET | Innovation Pharmaceuticals Inc.
Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method...
R360 Logo.jpg
Resilience360 and Riskpulse Release Report on Supply Chain Impacts of 2020 Hurricane and Tropical Storm Season
May 19, 2020 09:06 ET | Resilience360
-- Report outlines how hurricane season could compound supply chain vulnerabilities exposed by Covid-19 -- SAN MARCOS, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Resilience360 and Riskpulse have...
Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4
April 27, 2020 09:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been...
Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19
April 01, 2020 08:21 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today it has received data...
Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions
March 17, 2020 07:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the...
U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week
March 10, 2020 08:20 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...
Innovation Pharmaceuticals Provides Scientific Rationale and Clinical Development Perspectives for Brilacidin as a Potential Novel Coronavirus COVID-19 Treatment
March 02, 2020 07:00 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- March 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to...
TOMI Environmental Solutions, Inc. Logo
SteraMist Takes the Fight to the Coronavirus Worldwide - China, Hong Kong, Thailand, Singapore, Israel and the United Kingdom
February 27, 2020 09:30 ET | TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination, utilizing...
R360 Logo.jpg
Resilience360 Annual Risk Report Reveals Impacts of 2019 Supply Chain Disruptions and Predicts 2020 Supply Chain Risks
February 27, 2020 09:27 ET | Resilience360
TROISDORF, Germany, Feb. 27, 2020 (GLOBE NEWSWIRE) -- The annual Risk Report from supply chain risk management platform Resilience360 summarizes the significant supply chain challenges of the last...